Forest Laboratories, Inc. to Present Cariprazine & Levomilnacipran Results from Phase 3 Trials at American Psychiatric Associ...
May 04 2012 - 8:59AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) today announced it will be
presenting data on two late-stage development products, cariprazine
and levomilnacipran, at the American Psychiatric Association (APA)
Annual Meeting scheduled May 5-9, 2012 in Philadelphia, PA. Data on
cariprazine, an investigational antipsychotic agent, includes
additional details from a Phase III trial for acute mania in
bipolar I disorder and results from an open-label extension study
in schizophrenia. Separately, data on levomilnacipran, an
investigational agent for the treatment of adults with major
depressive disorder (MDD), includes additional analyses of Phase
III trial results.
The cariprazine results will be announced in 2 poster
presentations:
- Safety and Tolerability of Cariprazine
in the Long-Term Treatment of Schizophrenia: Results From a 48-Week
Extension Study (Poster NR6-50: Monday, May 7 from 11:00 am -
12:30 pm EDT)
- Cariprazine in the Treatment of Acute
Mania in Bipolar Disorder: A Double-Blind, Placebo-Controlled,
Phase III Trial (Poster NR9-42: Tuesday, May 8 from 11:00 am -
12:30 pm EDT)
The levomilnacipran results will be announced in 4 poster
presentations:
- Levomilnacipran in the Treatment of
Major Depressive Disorder: Functional Health and Well-Being
Efficacy Results From a Phase III Clinical Trial (Poster NR4-51:
Sunday, May 6 from 1:00 pm - 3:00 pm EDT)
- Levomilnacipran in the Treatment of
Major Depressive Disorder: An Analysis of Efficacy Data From 2
Phase III Studies (Poster NR9-33: Tuesday, May 8 from 11:00 am -
12:30 pm EDT)
- Levomilnacipran in the Treatment of
Major Depressive Disorder: An Analysis of Safety and Tolerability
Data From 2 Randomized Placebo-Controlled Trials (Poster NR9-36:
Tuesday, May 8 from 11:00 am - 12:30 pm EDT)
- The Efficacy of Levomilnacipran in the
Treatment of Major Depressive Disorder: Results From a Phase III
Clinical Trial (Poster NR9-48: Tuesday, May 8 from 11:00 am - 12:30
pm EDT)
About Cariprazine
Cariprazine, discovered by researchers at Gedeon Richter, is an
orally active, potent dopamine D3-preferring D3/D2 receptor partial
agonist. Cariprazine has a low potency at other receptor sites such
as 5-HT2C, histamine H1, muscarinic, and adrenergic receptor sites
which have been associated with adverse events. Cariprazine is also
under development for the treatment of bipolar depression, and as
an adjunct treatment for MDD.
Forest Laboratories Inc. and Gedeon Richter Ltd. are parties to
a collaboration agreement for Cariprazine. Forest has exclusive
rights to cariprazine in the US. and Canada and Gedeon Richter has
rights in the rest of the world.
About Levomilnacipran
Levomilnacipran (1S, 2R-milnacipran), an enantiomer of racemic
milnacipran, is protected by a method of use patent that extends
through June 2023, without patent term extension. Levomilnacipran
is an SNRI that has greater potency for norepinephrine reuptake
inhibition than for serotonin reuptake inhibition in vitro without
directly affecting the uptake of dopamine or other
neurotransmitters. Levomilnacipran is given as a sustained-release
formulation dosed once daily.
Levomilnacipran was discovered by Pierre Fabre and is licensed
to Forest Laboratories, Inc., in the U.S. and Canada. Pierre Fabre
will be the active pharmaceutical ingredient (API) supplier.
About Forest Laboratories
Forest Laboratories' (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective and respiratory
medicine. The Company's pipeline, the most robust in its history,
includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024